These data suggest that intraperitoneal injection of the chimeric NKG2D-Fc-RO protein is capable of generating potent therapeutic antitumor effects against NKG2D ligand expressing ovarian tumors following adoptive transfer of OVA-specific CD8+ T cells. Here, CALR is linked to ovarian neoplasm.